Security
Jazz Pharmaceuticals plc Common Stock (Ireland) · JAZZ
JAZZNASDAQCommon stockCurrentCIK 1232524Updated Nov 9, 2026
Name history
JAZZ PHARMACEUTICALS INC · through Jan 18, 2012
JAZZ price & chart
Loading TradingView…
NASDAQ:JAZZ on TradingView ↗About the company
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare diseases - often with limited or no therapeutic options. We have a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide.
In the news
Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance USA - English USA - English News provided by Jazz Pharmaceuticals plc Nov 05, 2025, 16:05 ET Share this article Share to X Share this article Share to X – Modeyso™ approved as the first and only t ↗
Recent filings
144 filing
SCHEDULE 13G/A - filed by FMR LLC regarding Jazz Pharmaceuticals plc
4 filing
144 filing
10-Q filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 11,356,485,000Source | 12,255,716,000Source | 11,080,900,000Source | 10,944,141,000Source | 11,361,868,000Source | 11,859,600,000Source | 11,534,682,000Source | 11,327,075,000Source | 11,659,340,000Source | 12,012,257,000Source | 11,393,359,000Source | 10,835,255,000Source |
| GoodwillUSD | 1,827,483,000Source | 1,804,646,000Source | 1,799,800,000Source | 1,843,974,000Source | 1,735,931,000Source | 1,805,000,000Source | 1,760,045,000Source | 1,739,495,000Source | 1,829,340,000Source | 1,716,323,000Source | 1,753,130,000Source | 1,692,662,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 4,565,737,000Source | 5,144,217,000Source | 4,029,500,000Source | 4,768,987,000Source | 5,079,462,000Source | 4,203,800,000Source | 4,718,158,000Source | 5,235,496,000Source | 4,429,510,000Source | 4,755,695,000Source | 5,418,039,000Source | 5,794,437,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 1,326,070,000Source | 2,218,135,000Source | 1,619,800,000Source | 1,189,880,000Source | 1,355,802,000Source | 1,844,300,000Source | 1,861,946,000Source | 1,443,385,000Source | 1,391,899,000Source | 2,412,864,000Source | 1,506,310,000Source | 881,482,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 764,364,000Source | 723,639,000Source | 880,900,000Source | 714,004,000Source | 698,037,000Source | 836,300,000Source | 652,992,000Source | 707,095,000Source | 830,747,000Source | 716,765,000Source | 705,794,000Source | 651,493,000Source |
| Inventory, NetUSD | 483,111,000Source | 539,302,000Source | 443,000,000Source | 504,989,000Source | 542,555,000Source | 437,500,000Source | 492,776,000Source | 577,321,000Source | 416,962,000Source | 480,445,000Source | 597,039,000Source | 714,061,000Source |
| Assets, CurrentUSD | 3,755,878,000Source | 4,390,423,000Source | 3,968,200,000Source | 3,350,433,000Source | 3,681,666,000Source | 4,583,100,000Source | 4,127,817,000Source | 3,539,898,000Source | 4,166,043,000Source | 4,629,028,000Source | 3,435,428,000Source | 2,606,140,000Source |
| Operating Lease, Right-of-Use AssetUSD | 61,204,000Source | 77,164,000Source | 52,100,000Source | 63,082,000Source | 73,145,000Source | 55,800,000Source | 49,181,000Source | 61,637,000Source | 58,880,000Source | 53,582,000Source | 65,340,000Source | 73,326,000Source |
| Other Assets, NoncurrentUSD | 103,068,000Source | 75,231,000Source | 86,300,000Source | 121,271,000Source | 71,425,000Source | 94,700,000Source | 116,516,000Source | 70,780,000Source | 99,030,000Source | 114,482,000Source | 67,464,000Source | 55,139,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 6,000Source | 6,000Source | 0Source | 6,000Source | 6,000Source | 0Source | 6,000Source | 6,000Source | 6,000Source | 6,000Source | 6,000Source | 6,000Source |
| Retained Earnings (Accumulated Deficit)USD | 442,725,000Source | 936,232,000Source | 1,132,000,000Source | 191,313,000Source | 871,178,000Source | 939,200,000Source | 1,034,806,000Source | 864,038,000Source | 646,176,000Source | 1,127,347,000Source | 878,656,000Source | 733,586,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -569,898,000Source | -603,397,000Source | -662,500,000Source | -485,768,000Source | -888,227,000Source | -651,000,000Source | -785,610,000Source | -882,394,000Source | -568,598,000Source | -947,667,000Source | -842,147,000Source | -1,125,509,000Source |
| Stockholders' Equity Attributable to ParentUSD | 3,959,030,000Source | 4,171,067,000Source | 4,801,700,000Source | 3,706,400,000Source | 3,762,599,000Source | 4,532,300,000Source | 4,174,800,000Source | 3,696,461,000Source | 4,318,584,000Source | 4,093,756,000Source | 3,736,997,000Source | 3,085,734,000Source |
| Additional Paid in Capital, Common StockUSD | 4,085,669,000Source | 3,837,698,000Source | 4,331,600,000Source | 4,000,280,000Source | 3,779,114,000Source | 4,243,500,000Source | 3,925,161,000Source | 3,714,283,000Source | 4,240,472,000Source | 3,913,542,000Source | 3,699,954,000Source | 3,477,124,000Source |
| Liabilities and EquityUSD | 11,356,485,000Source | 12,255,716,000Source | 11,080,900,000Source | 10,944,141,000Source | 11,361,868,000Source | 11,859,600,000Source | 11,534,682,000Source | 11,327,075,000Source | 11,659,340,000Source | 12,012,257,000Source | 11,393,359,000Source | 10,835,255,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 2,274,102,000Source | 1,029,977,000Source | 2,230,800,000Source | 2,071,205,000Source | 1,556,025,000Source | 2,246,600,000Source | 1,222,610,000Source | 1,562,206,000Source | 2,242,521,000Source | 1,038,573,000Source | 1,536,692,000Source | 933,193,000Source |
| Operating Lease, Liability, CurrentUSD | — | — | — | — | — | — | — | — | 14,278,000Source | 14,331,000Source | 19,019,000Source | 15,557,000Source |
| Accounts Payable, CurrentUSD | 152,227,000Source | 85,425,000Source | 128,500,000Source | 89,366,000Source | 97,096,000Source | 100,000,000Source | 95,930,000Source | 80,976,000Source | 122,061,000Source | 77,869,000Source | 102,750,000Source | 90,758,000Source |
| Operating Lease, Liability, NoncurrentUSD | 53,426,000Source | 71,115,000Source | 43,600,000Source | 55,107,000Source | 67,617,000Source | 47,300,000Source | 38,780,000Source | 56,158,000Source | 50,892,000Source | 38,938,000Source | 59,225,000Source | 71,838,000Source |
| Deferred Income Tax Liabilities, NetUSD | 629,033,000Source | 791,784,000Source | 528,900,000Source | 682,123,000Source | 775,228,000Source | 547,700,000Source | 670,801,000Source | 809,714,000Source | 594,470,000Source | 676,736,000Source | 847,706,000Source | 944,337,000Source |
| Other Liabilities, NoncurrentUSD | 108,912,000Source | 110,971,000Source | 140,900,000Source | 93,731,000Source | 99,416,000Source | 161,500,000Source | 91,119,000Source | 97,425,000Source | 124,519,000Source | 86,614,000Source | 104,751,000Source | 106,812,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 1,001,556,000Source | 858,578,000Source | 1,030,000,000Source | 874,811,000Source | 800,993,000Source | 1,022,400,000Source | 1,063,918,000Source | 826,530,000Source | 1,034,170,000Source | 910,947,000Source | 793,914,000Source | 803,255,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | — | 116,491,000Source | 369,872,000Source | 568,090,000Source |
| Long-term Debt, Excluding Current Maturities | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Long-term Debt, Current MaturitiesUSD | 1,029,179,000Source | 31,000,000Source | 1,016,400,000Source | 1,028,478,000Source | 605,798,000Source | 1,030,500,000Source | 31,000,000Source | 605,375,000Source | 1,029,903,000Source | 31,000,000Source | 604,954,000Source | 31,000,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 4,331,982,000Source | 6,080,802,000Source | 3,335,000,000Source | 4,335,616,000Source | 5,100,983,000Source | 4,324,200,000Source | 5,336,481,000Source | 5,105,111,000Source | 4,328,354,000Source | 6,077,640,000Source | 5,107,988,000Source | 5,693,341,000Source |
| Cash, Cash Equivalents, and Short-term Investments | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | — | — | 41,600,000Source | 32,800,000Source | 30,400,000Source | 30,300,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 74,500,000Source | 67,700,000Source | 291,133,000Source | 248,045,000Source | 226,841,000Source | 221,996,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 6,500,000Source | -66,000,000Source | 106,279,000Source | 21,115,000Source | 51,883,000Source | 90,135,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 77,800,000Source | 35,600,000Source | 86,041,000Source | 45,542,000Source | 13,420,000Source | 49,642,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -21,400,000Source | 19,100,000Source | 39,851,000Source | -20,073,000Source | 9,603,000Source | -11,225,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | -66,200,000Source | -43,800,000Source | -444,971,000Source | -208,327,000Source | -260,217,000Source | -292,251,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | 408,200,000Source | 429,800,000Source | 1,355,773,000Source | 1,395,908,000Source | 1,092,007,000Source | 1,271,977,000Source |
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 0Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 123,100,000Source | -169,000,000Source | -1,509,913,000Source | -508,195,000Source | -163,062,000Source | -446,230,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 19,700,000Source | 13,900,000Source | 58,752,000Source | 38,070,000Source | 23,962,000Source | 29,046,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 103,600,000Source | 67,200,000Source | 75,220,000Source | 57,753,000Source | 50,952,000Source | 45,443,000Source |
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | — | — | 125,023,000Source | 311,429,000Source | 269,761,000Source | 54,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -78,500,000Source | -813,500,000Source | -873,380,000Source | 20,516,000Source | -305,254,000Source | -529,491,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 452,400,000Source | -551,000,000Source | -1,020,965,000Source | 906,554,000Source | 624,828,000Source | 290,034,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 1,326,070,000Source | 2,218,135,000Source | 1,619,800,000Source | 1,189,900,000Source | 1,844,300,000Source | 1,861,900,000Source | 1,391,899,000Source | 2,412,864,000Source | 1,506,310,000Source | 881,482,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 248,553,000Source | 314,822,000Source | 333,112,000Source | 270,671,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 121,808,000Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | -400,000Source | 1,700,000Source | 6,555,000Source | -1,675,000Source | 1,137,000Source | -6,222,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 88,125,000Source | 59,760,000Source | 73,300,000Source | 64,500,000Source | 74,500,000Source | 67,700,000Source | 291,133,000Source | 248,045,000Source | 226,841,000Source | 221,996,000Source |
| Amortization of Debt Issuance CostsUSD | — | — | — | — | — | — | — | — | — | — | 4,200,000Source | — |
| Amortization of Intangible AssetsUSD | — | — | 168,368,000Source | 157,457,000Source | 170,000,000Source | 162,100,000Source | 172,300,000Source | 154,400,000Source | 654,661,000Source | 627,313,000Source | 608,284,000Source | 599,169,000Source |
| Deferred Other Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -13,582,000Source | -11,481,000Source | -8,990,000Source | -11,144,000Source |
| DepreciationUSD | — | — | — | — | — | — | 9,100,000Source | 10,400,000Source | 41,636,000Source | 32,754,000Source | 30,412,000Source | 30,302,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | 102,000Source | -701,000Source | -100,000Source | -1,800,000Source | 2,500,000Source | -200,000Source | -2,568,000Source | -8,182,000Source | 8,787,000Source | -19,014,000Source |
| Gain (Loss) on Disposition of BusinessUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | -37,704,000Source |
| GoodwillUSD | — | — | 1,827,483,000Source | 1,804,646,000Source | 1,799,800,000Source | 1,843,974,000Source | 1,805,000,000Source | 1,760,045,000Source | 1,829,340,000Source | 1,716,323,000Source | 1,753,130,000Source | 1,692,662,000Source |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | — |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | -47,000Source | -285,000Source | -100,000Source | -100,000Source | 0Source | -500,000Source | -732,000Source | -1,660,000Source | -3,009,000Source | -9,921,000Source |
| Income Tax Expense (Benefit)USD | — | — | -242,424,000Source | -14,533,000Source | 18,100,000Source | -17,200,000Source | 6,100,000Source | -17,800,000Source | -272,443,000Source | -91,429,000Source | -119,912,000Source | -158,645,000Source |
| Investment Income, InterestUSD | — | — | 18,600,000Source | 26,000,000Source | 25,300,000Source | 19,100,000Source | 23,400,000Source | 27,600,000Source | 85,800,000Source | 106,300,000Source | 65,100,000Source | 11,500,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 251,412,000Source | 215,055,000Source | 192,800,000Source | -718,500,000Source | 293,100,000Source | -92,500,000Source | -356,148,000Source | 560,120,000Source | 414,832,000Source | -224,060,000Source |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | 500,000,000Source | 440,100,000Source | 1,830,275,000Source | 1,305,125,000Source | 390,100,000Source | 61,036,000Source |
| Cash, Cash Equivalents, and Short-term Investments | — | — | — | — | —Source | — | —Source | — | — | — | — | — |
| Gain (Loss) on Disposition of Other Assets | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 1,126,107,000Source | 1,054,969,000Source | 1,208,300,000Source | 1,045,700,000Source | 1,068,900,000Source | 897,800,000Source | 4,267,586,000Source | 4,068,950,000Source | 3,834,204,000Source | 3,659,374,000Source |
| Selling, General and Administrative ExpenseUSD | — | — | 530,647,000Source | 325,772,000Source | 389,200,000Source | 358,400,000Source | 352,700,000Source | 514,000,000Source | 1,809,271,000Source | 1,385,294,000Source | 1,343,105,000Source | 1,416,967,000Source |
| Operating Income (Loss)USD | — | — | 57,509,000Source | 260,210,000Source | 248,200,000Source | -686,400,000Source | 336,600,000Source | -55,900,000Source | -430,240,000Source | 716,630,000Source | 578,580,000Source | -65,528,000Source |
| Income Tax Expense (Benefit)USD | — | — | -242,424,000Source | -14,533,000Source | 18,100,000Source | -17,200,000Source | 6,100,000Source | -17,800,000Source | -272,443,000Source | -91,429,000Source | -119,912,000Source | -158,645,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 251,412,000Source | 215,055,000Source | 192,800,000Source | -718,500,000Source | 293,100,000Source | -92,500,000Source | -356,148,000Source | 560,120,000Source | 414,832,000Source | -224,060,000Source |
| Earnings Per Share, BasicUSD per share | — | — | 4.14Source | 3.5Source | 3.05Source | -11.74Source | 4.73Source | -1.52Source | -5.84Source | 9.06Source | 6.55Source | -3.58Source |
| Earnings Per Share, DilutedUSD per share | — | — | 4.08Source | 3.42Source | 2.78Source | -11.74Source | 4.43Source | -1.52Source | -5.84Source | 8.65Source | 6.1Source | -3.58Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 60,696,000Source | 61,414,000Source | 63,200,000Source | 61,200,000Source | 61,900,000Source | 61,000,000Source | 60,981,000Source | 61,838,000Source | 63,291,000Source | 62,539,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 61,606,000Source | 63,174,000Source | 69,400,000Source | 61,200,000Source | 66,100,000Source | 61,000,000Source | 60,981,000Source | 66,007,000Source | 72,066,000Source | 62,539,000Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 168,368,000Source | 157,457,000Source | 170,000,000Source | 162,100,000Source | 172,300,000Source | 154,400,000Source | 654,661,000Source | 627,313,000Source | 608,284,000Source | 599,169,000Source |
| Costs and ExpensesUSD | — | — | 1,068,598,000Source | 794,759,000Source | 960,100,000Source | 1,732,100,000Source | 732,300,000Source | 953,700,000Source | 4,697,826,000Source | 3,352,320,000Source | 3,255,624,000Source | 3,724,902,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 172,528,000Source | 116,898,000Source | 140,305,000Source | 133,606,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | 102,000Source | -701,000Source | -100,000Source | -1,800,000Source | 2,500,000Source | -200,000Source | -2,568,000Source | -8,182,000Source | 8,787,000Source | -19,014,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | 164,697,000Source | 497,860,000Source | 449,214,000Source | -50,311,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | -47,000Source | -285,000Source | -100,000Source | -100,000Source | 0Source | -500,000Source | -732,000Source | -1,660,000Source | -3,009,000Source | -9,921,000Source |
| Interest Expense, DebtUSD | — | — | — | — | — | — | — | — | — | — | 32,800,000Source | 32,800,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | -48,576,000Source | -58,702,000Source | -37,100,000Source | -47,400,000Source | -39,900,000Source | -53,700,000Source | -195,051,000Source | -238,097,000Source | -289,438,000Source | -288,242,000Source |
| Investment Income, InterestUSD | — | — | 18,600,000Source | 26,000,000Source | 25,300,000Source | 19,100,000Source | 23,400,000Source | 27,600,000Source | 85,800,000Source | 106,300,000Source | 65,100,000Source | 11,500,000Source |
Filing attachments
d127542dex41.htm · 8-K · 2026-08-31
Exhibit 4.1 Execution Version JAZZ INVESTMENTS I LIMITED, as Issuer JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY, as Guarantor AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee Indenture Dated as of August 31, 2026 1.875% Exchangeable Senior Notes due 2032 TABLE OF CONTENTS ARTICLE 1 DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 …
Read attachment ↗d127542dex991.htm · 8-K · 2026-08-31
Exhibit 99.1 Jazz Pharmaceuticals Announces Private Offering of $1.0 Billion of Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases DUBLIN, August 26, 2026 -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz Pharmaceuticals”) today announced that Jazz Investments I Limited, its wholly-owned subsidiary (the “Issuer”), intends to offer, subject to market conditions and other factors, $1.0 billion aggregate principal amount of exchangeable senior notes due 2032 (the “notes…
Read attachment ↗d127542dex992.htm · 8-K · 2026-08-31
Exhibit 99.2 Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases DUBLIN, August 27, 2026 - Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz Pharmaceuticals”) today announced the pricing of $1.1 billion aggregate principal amount of 1.875% exchangeable senior notes due 2032 (the “notes”) in a private offering (the “offering”) by Jazz Investments I Limited, its wholly-owned subsid…
Read attachment ↗d106596dex991.htm · 8-K · 2026-08-10
EX-99.1 2 d106596dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 FINAL Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio Adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1+ epilepsy Leverages Jazz development expertise and commercial strength in rare and severe epilepsies Transaction includes $820 million upfront payment DUBLIN and SAN DIEGO, August 10, 2026 - Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Actio Biosciences,…
Read attachment ↗jazzq42025ex41.htm · 10-K · 2026-02-24
Exhibit 4.1 DESCRIPTION OF SHARE CAPITAL The following description of the share capital of Jazz Pharmaceuticals plc, or the Company, is a summary. This summary does not purport to be complete and is qualified in its entirety by reference to the Irish Companies Act 2014 (as amended), or the Companies Act, and the complete text of the Company’s amended and restated memorandum and articles of association, which amended and restated memorandum and articles of association, or the Company’s Constitu…
Read attachment ↗d61589dex991.htm · 8-K · 2026-01-12
EX-99.1 2 d61589dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 January 2026 44th Annual J.P. Morgan Healthcare Conference Redefining Possibilities in Rare Disease Renee Gala, President & CEO Transforming Lives. Redefining Possibilities. Caution Concerning Forward-Looking Statements This presentation contains forward-looking statements and financial targets, including, but not limited to, statements related to: the Company’s growth prospects and future financial and operating results, including t…
Read attachment ↗